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Abstract
Objectives: To assess whether switching patients with suboptimally controlled pulmonary arterial hypertension from bosentan or ambrisentan to macitentan would improve six-minute walk
test (6MWT) distance and World Health Organization functional class.
Methods: This was a retrospective cohort analysis of 37 patients from a single center. Patients
were separated into three heterogeneous treatment groups and followed for 18 months: switch
group (n ¼ 14): patients switched to macitentan from bosentan/ambrisentan; added group
(n ¼ 11): patients who began macitentan as de novo therapy (n ¼ 5) or who added macitentan
to an existing sildenafil regimen (n ¼ 6); and control group (n ¼ 12): patients for whom sildenafil
and/or bosentan/ambrisentan therapy was unchanged.
Results: Mortality was observed in two patients (one each, switch and added groups). Patients in
the control group had one hospital admission and 100% survival. There was significant improvement in functional class for the switch and added groups. Statistically significant improvement was
observed in 6MWT distance in the added group alone. Overall, 92% of patients continued
macitentan throughout the study.
Conclusion: Macitentan was well tolerated. For bosentan/ambrisentan-treated patients with
suboptimally controlled pulmonary arterial hypertension, switching to macitentan may facilitate
an improvement in functional class.
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Introduction
Pulmonary hypertension (PH) is associated
with impaired quality of life, poor functional capacity, reduced survival, and mean
pulmonary artery pressure (mPAP)
 25 mmHg at rest.1 There are five types
of PH.2,3 Pulmonary arterial hypertension
(PAH), a rare form of PH, comprises
PAPm  25 mmHg, combined with pulmonary capillary wedge pressure  15 mmHg.3
PAH affects pulmonary circulation, but can
occur secondary to other medical conditions.3 The Armadale PH study suggested
a prevalence of 15/100,000 people with
PAH in a Western Australian population.4
Traditionally, patients with PAH have had
very high morbidity and mortality.5
However, the prognosis of PAH has
improved with the advent of targeted
PAH therapies.4
The World Health Organization (WHO)
categorizes PH into four classes of functional limitation: I (nil) to IV (severe).2 Patients
with WHO functional Class II and higher
are generally eligible for targeted therapies,5
including endothelin-1 receptor antagonists
(ERAs), phosphodiesterase-5 inhibitors
(PDE5) and synthetic prostacyclin/prostaglandin analogs.6 Other therapies include
prostanoid receptor agonists.7 A recent
meta-analysis showed that therapy with
prostacyclin, an ERA, or a PDE5 inhibitor
improved mortality, compared with controls.8,9 Nonetheless, morbidity and mortality from PAH remain high.
In September 2014, a new ERA—macitentan—was made available under the

Pharmaceutical
Benefits
Scheme
in
Australia.10
Macitentan
demonstrates
enhanced receptor binding, potency, and
receptor occupancy half-life, compared
with other ERAs.8 Thus, macitentan may
be superior to either ambrisentan or bosentan for treatment of PAH. Compared with
placebo, participants on macitentan have
shown improved exercise capacity and
WHO functional class;11 macitentan significantly reduced morbidity and mortality,
even among patients who received macitentan as an addition to established PAH therapy.12 There is no notable increase in the
risk of hepatotoxicity or peripheral edema
on macitentan.13 Despite these theoretical
benefits of macitentan, to our knowledge,
no studies have directly compared macitentan with other available ERAs, or any other
targeted therapies. Thus, an analysis is
needed to determine whether a switch of
ERAs to macitentan is associated with
functional improvement in patients with
suboptimal response to first-line therapy.
We hypothesized that in adult patients
with
clinician-determined
suboptimal
response to bosentan or ambrisentan, a
switch to macitentan would be associated
with improved outcomes as measured by
WHO functional class, six-minute walk
test (6MWT), and echocardiographic
parameters as well as reduced number of
hospitalizations, irrespective of concurrent
PDE5 inhibitor use. Furthermore, we
hypothesized that drug tolerability would
be improved in patients switched
to macitentan.

Tynan et al.

Materials and methods
Study design
Ethics approval was granted through a lowrisk application to the Human Ethics
Research
Committee
through
the
University of Notre Dame Australia. This
retrospective cohort study involved the
analysis of cardiopulmonary, clinical, and
exercise parameters from the records of
patients who underwent treatment for
PAH by one clinician in a private clinic in
Australia. A public notification was posted
in the examination rooms of the clinic to
notify patients of the study.
The patients were classified into
three treatment groups (described in
“Participants” subsection, below) based on
treatment status, which was determined
prior to the study. The treating clinician
used a combination of objective measures
to determine which patients were stable
and which patients showed a lack of
response to first-line therapy; these included
WHO functional class, 6MWT distance,
echocardiography, tolerance to medication,
and hospitalization requirement. Patients
were then allocated to the appropriate
treatment groups.
Data were retrospectively collected from
patient records for the period from January
2014 through September 2016. All data
reflected conventional clinical practice
and clinical management decisions, which
were not impacted by the current
study. Patients with either prevalent
(length of diagnosis  6 months) or incident
(length of diagnosis < 6 months) PAH
were included.

Participants
Records of patients 18 years of age who
were diagnosed with Group 1 PH (i.e.,
PAH), and who were eligible for
Pharmaceutical Benefits Scheme-subsidized
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targeted therapies, were included in the
study. For the purpose of analysis, patients
were divided into three groups based upon
management decisions. The treating clinician made these decisions prior to beginning any research with regard to treatment
of the patients.
The group of interest (switch group) consisted of patients who were switched from
bosentan or ambrisentan, based on the
clinician’s
assessment
of
suboptimal response.
The first comparator group (added
group) consisted of patients who began
macitentan as first-line therapy or who
added macitentan therapy to existing sildenafil therapy.
The second comparator group (control
group) consisted of patients who were
judged by the treating clinician to have
stable PAH; in these patients, therapy
with sildenafil and/or bosentan/ambrisentan was unchanged.

Variables
In addition to survival data, information
was collected from all patient records
regarding demographic variables (age,
sex), clinical diagnosis (type of PAH), and
duration since diagnosis. Both WHO functional class and the 6MWT distance in
meters were recorded as functional outcomes. Furthermore, the following echocardiography measures were recorded for each
patient: right ventricular size, right ventricular systolic function, and pulmonary
artery systolic pressure (PASP). The frequencies of all-cause hospitalization and
mortality were recorded, as were the incidences of all known side effects of macitentan and other ERAs (e.g., abnormal liver
function tests, gastrointestinal upset, and
anemia). The use of other therapies, including diuretics, was also noted.
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Data analysis
Demographic data (de-identified) for all
patients were recorded in an Excel spreadsheet and coded appropriately. Stability of
PAH was determined via the analysis of the
outcome measures listed in variables.
Differences among groups were identified
using analyses of variance and analyses of
covariance for continuous variables. Post
hoc analyses involving small sample numbers and repeated measures data were performed using Friedman’s nonparametric
test for related samples. The nonparametric
Wilcoxon signed-rank test was used to compare changes in categorical rank data.
Measures of association for categorical
data were tested using chi-squared analyses.
SPSS for Windows (version 25.0.0.1; IBM
Corp., Armonk, NY, USA) was used to
perform statistical comparisons. A p-value
of < 0.05 was considered to be significant.
Missing data were addressed as follows.
Initially, all demographic information was
collected. If information regarding 6MWT
was unavailable, this parameter was left
blank. For patients with insufficient tricuspid regurgitation, no numerical value was

assigned for PASP. Regarding echocardiography, some reports did not describe systolic function and size; thus, this information
was coded as absent. Patients who had
missing data were excluded from analyses
involving those parameters.

Results
This exploratory study enrolled a convenience sample of 37 patients, which is considerable for a rare disease. All had PAH
confirmed by right heart catheterization.
Non-PAH causes of pre-capillary PH were
excluded, based on known diagnostic and
assessment protocols.1 There were 14
patients in the switch group, 11 patients in
the added group, and 12 patients in the control group. One patient each in the switch
and added groups died. The three groups
were similar in age, sex distribution, and
type of PAH (Table 1).
Regarding WHO Functional Class,
Figure 1 shows the changes in actual rank
for each patient. Wilcoxon signed rank test
between functional class at baseline and at
6 months showed significant changes for the
switch (z ¼ 2.91, p ¼ 0.004) and added

Table 1. Demographic characteristics.

Age (years,  SD)
Female sex (%)
PAH etiology
Idiopathic
Scleroderma
PAH type
Incident
Prevalent
Prior medication
Bosentan
Ambrisentan
None
Sildenafil
Bosentan þ sildenafil

Switch (n ¼ 14)

Added (n ¼ 11)

Control (n ¼ 12)

p-value

63  13
86%

65  5
73%

74  9
83%

0.114
0.927
0.818

64%
36%

55%
45%

67%
33%

3
11

8
3

2
10

12
2
0
0
0

0
0
5
6
0

9
0
0
1
2

Not compared

Not compared

SD, standard deviation; PAH, pulmonary arterial hypertension.
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Figure 1. World Health Organization functional class. WHO, World Health Organization; 6 m, 6 months.

Table 2. Six-minute walk test distance.
Group

Time point

Distance
(m, mean  SD)

Switch

Baseline
3 months
6 months
Baseline
3 months
6 months
Baseline
3 months
6 months

371  28
415  29
404  42
334  28
393  29
415  42
484  28
464  29
461  42

Added

Control

p-value
0.17

0.01

0.88

SD, standard deviation.

groups (z ¼ 2.12, p ¼ 0.03), but not for the
control group (z ¼ 0.00). For 6MWT
(Table 2), by 6 months there was a 37-m
improvement in the switch group (not statistically significant), a 98-m improvement
in the added group (p¼0.01), and no significant change in the control group. There
was no difference between the switch and

control groups, whereas there was a difference between the added and control groups
(p ¼ 0.03). There was weak statistical evidence for a difference between the switch
and added groups (Figure 2).
Given the small study numbers, a
Friedman’s statistic was calculated to determine whether echocardiography scores differed among the three measurement points
for each group. The v2 test did not show
significant differences in right ventricular
size or right ventricular systolic function
for any of the groups (Figures 3 and 4).
PASP at echocardiography was only
recorded for patients with sufficient tricuspid regurgitation (Figure 5). In the switch
group, eight patients at baseline had insufficient tricuspid regurgitation; thus, no data
were available for analysis in these patients.
Similarly, two patients in the control group
and one patient in the added group had
insufficient tricuspid regurgitation and
were excluded from analysis. There was no
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Figure 2. Mean six-minute walk test distance in meters.

Figure 3. Echocardiography analysis of right ventricular systolic function. 6 m, 6 months; Mild-Mod, mild to
moderate dysfunction.
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Figure 4. Echocardiography analysis of right ventricle size. 6 m, 6 months.

statistically significant difference in PASP
for the switch (v2 ¼ 3.5), added (v2 ¼ 1.6),
and control groups (v2 ¼ 2.1).
Eleven patients had at least one hospital
admission. Mortality was 2/37 (one each in
the switch and added groups) with an annualized mortality of 3.6%. Patients in the control group remained stable with one hospital
admission and 100% survival. Overall, 92%
of patients continued macitentan throughout
the study. One patient in the switch group
stopped macitentan due to anemia; another
patient in the switch group stopped all therapy, received palliative therapy, and died
shortly thereafter (Table 3).

Discussion
This study found that, in ERA-treated
patients who did not show well-controlled
PAH (based on WHO Functional Class,
6MWT distance, and echocardiography

features of right ventricular failure), switching to macitentan was associated with a statistically significant improvement in
functional class. These findings confirmed
that macitentan is well tolerated and effective for treatment of PAH.
There was an improvement in the WHO
functional class in the switch group.
Notably, the WHO functional class is a
robust measure and has been used to
guide therapy.3,14,15 To our knowledge this
is the first study to show an improvement in
WHO functional class following a switch
from an existing ERA regimen to macitentan. Additionally, the 6MWT is a widely
used, simple, and non-invasive test that
measures reduced exercise capacity and
provides an estimate of aerobic fitness in
patients with PAH.2,15 In this study, there
was a 37-m improvement in the 6MWT distance in patients who switched to macitentan, compared with no change in patients
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Figure 5. Mean echocardiography analysis of pulmonary artery systolic pressure. PASP, pulmonary artery
systolic pressure.

Table 3. Frequency of side effects for each group at 6 months*.

Discontinued drug due to side effects
Stopped or changed medication
Side effects
GIT
Liver derangement
Anemia (Hemoglobin < 100)
New treatment required
Diuretics
Hospitalizations
Mortality†

Switch (n ¼ 14)

Added (n ¼ 11)

Control (n ¼ 12)

1
2

0
0

0
1

0
2
2

0
2
3

0
2
1

4
5
1

6
4
1

2
2
0

†

Both patients who died were World Health Organization functional Class IV at baseline.
*Because of the small numbers of reported side effects, no data analysis was performed using data shown in this table.

who remained on their previous therapy;
however, this improvement was not statistically significant.
Echocardiographic assessment of right
ventricular function is routine for disease

monitoring; however, its value in following
patients—to determine response to therapy—has not been established.16–18 Our findings also showed no clear value of right
ventricular function for determining
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response to therapy: there were no measurable differences in the switch or added
groups with regard to right ventricular systolic function or size, nor were there differences in PASP. Clinicians should exercise
caution in the use of echocardiography for
monitoring disease progression; further
investigation is needed regarding noninvasive assessments of disease in patients
with PAH.13,19
This study had several limitations. Most
importantly, it was retrospective and some
data were missing. Furthermore, the sample
size was relatively small, such that it was
not powered to determine differences in
mortality. Notably, mortality and hospitalizations for PAH occurred only in
macitentan-treated patients. This was
expected, as these groups contained patients
who had shown poor response to first-line
therapy, suggesting poorer overall health at
baseline. Two patients died, both from progressive heart failure; moreover, both were
in WHO functional class IV at the beginning of the study period. Additionally,
more patients in the switch and added
groups required hospitalization and the
addition of diuretic treatment; this may
also have been because these patients had
poorer overall health at baseline; however,
we cannot rule out that these effects may
have been directly caused by macitentan.
Finally, this was not a randomized study;
thus, the highly heterogeneous patient
groups were not directly comparable at
baseline. However, this study reflects reallife situations, in that clinicians often
encounter difficulty with regard to management of disease in patients with suboptimal
response to therapy. Importantly, however,
we have shown that in a group of patients
with poorly controlled PAH on existing
ERA regimens, switching to a plausibly
more effective ERA (macitentan) may facilitate clinically meaningful improvements.
In summary, we found a significant
improvement in WHO functional class
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and 6MWT in patients who switched from
bosentan/ambrisentan to macitentan. To
our knowledge, this has not been previously
studied. We believe that the strength of this
study is that the parameters used in the
study are equivalent to those routinely
used in clinical practice, such that they are
available when determining the course of
treatment in patients with PAH. Switching
from bosentan or ambrisentan to macitentan is a therapeutic option available to clinicians who treat patients with suboptimal
response to therapy for PAH.
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